A dose-ranging, parallel group, split-face, single-blind phase II study of light emitting diode-red light (LED-RL) for skin scarring prevention: study protocol for a randomized controlled trial
Background Skin fibrosis is a significant global health problem that affects over 100 million people annually and has a profoundly negative impact on quality of life. Characterized by excessive fibroblast proliferation and collagen deposition, skin fibrosis underlies a wide spectrum of dermatologic...
Saved in:
| Published in | Current controlled trials in cardiovascular medicine Vol. 20; no. 1; pp. 432 - 10 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
BioMed Central
15.07.2019
BioMed Central Ltd BMC |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1745-6215 1745-6215 |
| DOI | 10.1186/s13063-019-3546-6 |
Cover
| Abstract | Background
Skin fibrosis is a significant global health problem that affects over 100 million people annually and has a profoundly negative impact on quality of life. Characterized by excessive fibroblast proliferation and collagen deposition, skin fibrosis underlies a wide spectrum of dermatologic conditions ranging from pathologic scars secondary to injury (e.g., burns, surgery, trauma) to immune-mediated diseases. Effective anti-scarring therapeutics remain an unmet need, underscoring the importance of developing novel approaches to treat and prevent skin fibrosis. Our in vitro data show that light emitting diode-red light (LED-RL) can modulate key cellular and molecular processes involved in skin fibrosis. In two phase I clinical trials (STARS 1 and STARS 2), we demonstrated the safety and tolerability of LED-RL at fluences of 160 J/cm
2
up to 480 J/cm
2
on normal human skin.
Methods/design
CURES (Cutaneous Understanding of Red-light Efficacy on Scarring) is a dose-ranging, randomized, parallel group, split-face, single-blind, mock-controlled phase II study to evaluate the efficacy of LED-RL to limit post-surgical skin fibrosis in subjects undergoing elective mini-facelift surgery. Thirty subjects will be randomly allocated to three treatment groups to receive LED-RL phototherapy or temperature-matched mock irradiation (control) to either periauricular incision site at fluences of 160 J/cm
2
, 320 J/cm
2
, or 480 J/cm
2
. Starting one week post-surgery (postoperative days 4–8), treatments will be administered three times weekly for three consecutive weeks, followed by efficacy assessments at 30 days, 3 months, and 6 months. The primary endpoint is the difference in scar pliability between LED-RL-treated and control sites as determined by skin elasticity and induration measurements. Secondary outcomes include clinical and photographic evaluations of scars, 3D skin imaging analysis, histological and molecular analyses, and adverse events.
Discussion
LED-RL is a therapeutic modality of increasing importance in dermatology, and has the potential to limit skin fibrosis clinically by decreasing dermal fibroblast activity and collagen production. The administration of LED-RL phototherapy in the early postoperative period may optimize wound healing and prevent excessive scarring. The results from this study may change the current treatment paradigm for fibrotic skin diseases and help to pioneer LED-RL as a safe, non-invasive, cost-effective, portable, at-home therapy for scars.
Trial registration
ClinicalTrials.gov,
NCT03795116
. Registered on 20 December 2018. |
|---|---|
| AbstractList | Background
Skin fibrosis is a significant global health problem that affects over 100 million people annually and has a profoundly negative impact on quality of life. Characterized by excessive fibroblast proliferation and collagen deposition, skin fibrosis underlies a wide spectrum of dermatologic conditions ranging from pathologic scars secondary to injury (e.g., burns, surgery, trauma) to immune-mediated diseases. Effective anti-scarring therapeutics remain an unmet need, underscoring the importance of developing novel approaches to treat and prevent skin fibrosis. Our in vitro data show that light emitting diode-red light (LED-RL) can modulate key cellular and molecular processes involved in skin fibrosis. In two phase I clinical trials (STARS 1 and STARS 2), we demonstrated the safety and tolerability of LED-RL at fluences of 160 J/cm
2
up to 480 J/cm
2
on normal human skin.
Methods/design
CURES (Cutaneous Understanding of Red-light Efficacy on Scarring) is a dose-ranging, randomized, parallel group, split-face, single-blind, mock-controlled phase II study to evaluate the efficacy of LED-RL to limit post-surgical skin fibrosis in subjects undergoing elective mini-facelift surgery. Thirty subjects will be randomly allocated to three treatment groups to receive LED-RL phototherapy or temperature-matched mock irradiation (control) to either periauricular incision site at fluences of 160 J/cm
2
, 320 J/cm
2
, or 480 J/cm
2
. Starting one week post-surgery (postoperative days 4–8), treatments will be administered three times weekly for three consecutive weeks, followed by efficacy assessments at 30 days, 3 months, and 6 months. The primary endpoint is the difference in scar pliability between LED-RL-treated and control sites as determined by skin elasticity and induration measurements. Secondary outcomes include clinical and photographic evaluations of scars, 3D skin imaging analysis, histological and molecular analyses, and adverse events.
Discussion
LED-RL is a therapeutic modality of increasing importance in dermatology, and has the potential to limit skin fibrosis clinically by decreasing dermal fibroblast activity and collagen production. The administration of LED-RL phototherapy in the early postoperative period may optimize wound healing and prevent excessive scarring. The results from this study may change the current treatment paradigm for fibrotic skin diseases and help to pioneer LED-RL as a safe, non-invasive, cost-effective, portable, at-home therapy for scars.
Trial registration
ClinicalTrials.gov,
NCT03795116
. Registered on 20 December 2018. Skin fibrosis is a significant global health problem that affects over 100 million people annually and has a profoundly negative impact on quality of life. Characterized by excessive fibroblast proliferation and collagen deposition, skin fibrosis underlies a wide spectrum of dermatologic conditions ranging from pathologic scars secondary to injury (e.g., burns, surgery, trauma) to immune-mediated diseases. Effective anti-scarring therapeutics remain an unmet need, underscoring the importance of developing novel approaches to treat and prevent skin fibrosis. Our in vitro data show that light emitting diode-red light (LED-RL) can modulate key cellular and molecular processes involved in skin fibrosis. In two phase I clinical trials (STARS 1 and STARS 2), we demonstrated the safety and tolerability of LED-RL at fluences of 160 J/cm2 up to 480 J/cm2 on normal human skin.BACKGROUNDSkin fibrosis is a significant global health problem that affects over 100 million people annually and has a profoundly negative impact on quality of life. Characterized by excessive fibroblast proliferation and collagen deposition, skin fibrosis underlies a wide spectrum of dermatologic conditions ranging from pathologic scars secondary to injury (e.g., burns, surgery, trauma) to immune-mediated diseases. Effective anti-scarring therapeutics remain an unmet need, underscoring the importance of developing novel approaches to treat and prevent skin fibrosis. Our in vitro data show that light emitting diode-red light (LED-RL) can modulate key cellular and molecular processes involved in skin fibrosis. In two phase I clinical trials (STARS 1 and STARS 2), we demonstrated the safety and tolerability of LED-RL at fluences of 160 J/cm2 up to 480 J/cm2 on normal human skin.CURES (Cutaneous Understanding of Red-light Efficacy on Scarring) is a dose-ranging, randomized, parallel group, split-face, single-blind, mock-controlled phase II study to evaluate the efficacy of LED-RL to limit post-surgical skin fibrosis in subjects undergoing elective mini-facelift surgery. Thirty subjects will be randomly allocated to three treatment groups to receive LED-RL phototherapy or temperature-matched mock irradiation (control) to either periauricular incision site at fluences of 160 J/cm2, 320 J/cm2, or 480 J/cm2. Starting one week post-surgery (postoperative days 4-8), treatments will be administered three times weekly for three consecutive weeks, followed by efficacy assessments at 30 days, 3 months, and 6 months. The primary endpoint is the difference in scar pliability between LED-RL-treated and control sites as determined by skin elasticity and induration measurements. Secondary outcomes include clinical and photographic evaluations of scars, 3D skin imaging analysis, histological and molecular analyses, and adverse events.METHODS/DESIGNCURES (Cutaneous Understanding of Red-light Efficacy on Scarring) is a dose-ranging, randomized, parallel group, split-face, single-blind, mock-controlled phase II study to evaluate the efficacy of LED-RL to limit post-surgical skin fibrosis in subjects undergoing elective mini-facelift surgery. Thirty subjects will be randomly allocated to three treatment groups to receive LED-RL phototherapy or temperature-matched mock irradiation (control) to either periauricular incision site at fluences of 160 J/cm2, 320 J/cm2, or 480 J/cm2. Starting one week post-surgery (postoperative days 4-8), treatments will be administered three times weekly for three consecutive weeks, followed by efficacy assessments at 30 days, 3 months, and 6 months. The primary endpoint is the difference in scar pliability between LED-RL-treated and control sites as determined by skin elasticity and induration measurements. Secondary outcomes include clinical and photographic evaluations of scars, 3D skin imaging analysis, histological and molecular analyses, and adverse events.LED-RL is a therapeutic modality of increasing importance in dermatology, and has the potential to limit skin fibrosis clinically by decreasing dermal fibroblast activity and collagen production. The administration of LED-RL phototherapy in the early postoperative period may optimize wound healing and prevent excessive scarring. The results from this study may change the current treatment paradigm for fibrotic skin diseases and help to pioneer LED-RL as a safe, non-invasive, cost-effective, portable, at-home therapy for scars.DISCUSSIONLED-RL is a therapeutic modality of increasing importance in dermatology, and has the potential to limit skin fibrosis clinically by decreasing dermal fibroblast activity and collagen production. The administration of LED-RL phototherapy in the early postoperative period may optimize wound healing and prevent excessive scarring. The results from this study may change the current treatment paradigm for fibrotic skin diseases and help to pioneer LED-RL as a safe, non-invasive, cost-effective, portable, at-home therapy for scars.ClinicalTrials.gov, NCT03795116 . Registered on 20 December 2018.TRIAL REGISTRATIONClinicalTrials.gov, NCT03795116 . Registered on 20 December 2018. BackgroundSkin fibrosis is a significant global health problem that affects over 100 million people annually and has a profoundly negative impact on quality of life. Characterized by excessive fibroblast proliferation and collagen deposition, skin fibrosis underlies a wide spectrum of dermatologic conditions ranging from pathologic scars secondary to injury (e.g., burns, surgery, trauma) to immune-mediated diseases. Effective anti-scarring therapeutics remain an unmet need, underscoring the importance of developing novel approaches to treat and prevent skin fibrosis. Our in vitro data show that light emitting diode-red light (LED-RL) can modulate key cellular and molecular processes involved in skin fibrosis. In two phase I clinical trials (STARS 1 and STARS 2), we demonstrated the safety and tolerability of LED-RL at fluences of 160 J/cm2 up to 480 J/cm2 on normal human skin.Methods/designCURES (Cutaneous Understanding of Red-light Efficacy on Scarring) is a dose-ranging, randomized, parallel group, split-face, single-blind, mock-controlled phase II study to evaluate the efficacy of LED-RL to limit post-surgical skin fibrosis in subjects undergoing elective mini-facelift surgery. Thirty subjects will be randomly allocated to three treatment groups to receive LED-RL phototherapy or temperature-matched mock irradiation (control) to either periauricular incision site at fluences of 160 J/cm2, 320 J/cm2, or 480 J/cm2. Starting one week post-surgery (postoperative days 4–8), treatments will be administered three times weekly for three consecutive weeks, followed by efficacy assessments at 30 days, 3 months, and 6 months. The primary endpoint is the difference in scar pliability between LED-RL-treated and control sites as determined by skin elasticity and induration measurements. Secondary outcomes include clinical and photographic evaluations of scars, 3D skin imaging analysis, histological and molecular analyses, and adverse events.DiscussionLED-RL is a therapeutic modality of increasing importance in dermatology, and has the potential to limit skin fibrosis clinically by decreasing dermal fibroblast activity and collagen production. The administration of LED-RL phototherapy in the early postoperative period may optimize wound healing and prevent excessive scarring. The results from this study may change the current treatment paradigm for fibrotic skin diseases and help to pioneer LED-RL as a safe, non-invasive, cost-effective, portable, at-home therapy for scars.Trial registrationClinicalTrials.gov, NCT03795116. Registered on 20 December 2018. Abstract Background Skin fibrosis is a significant global health problem that affects over 100 million people annually and has a profoundly negative impact on quality of life. Characterized by excessive fibroblast proliferation and collagen deposition, skin fibrosis underlies a wide spectrum of dermatologic conditions ranging from pathologic scars secondary to injury (e.g., burns, surgery, trauma) to immune-mediated diseases. Effective anti-scarring therapeutics remain an unmet need, underscoring the importance of developing novel approaches to treat and prevent skin fibrosis. Our in vitro data show that light emitting diode-red light (LED-RL) can modulate key cellular and molecular processes involved in skin fibrosis. In two phase I clinical trials (STARS 1 and STARS 2), we demonstrated the safety and tolerability of LED-RL at fluences of 160 J/cm2 up to 480 J/cm2 on normal human skin. Methods/design CURES (Cutaneous Understanding of Red-light Efficacy on Scarring) is a dose-ranging, randomized, parallel group, split-face, single-blind, mock-controlled phase II study to evaluate the efficacy of LED-RL to limit post-surgical skin fibrosis in subjects undergoing elective mini-facelift surgery. Thirty subjects will be randomly allocated to three treatment groups to receive LED-RL phototherapy or temperature-matched mock irradiation (control) to either periauricular incision site at fluences of 160 J/cm2, 320 J/cm2, or 480 J/cm2. Starting one week post-surgery (postoperative days 4–8), treatments will be administered three times weekly for three consecutive weeks, followed by efficacy assessments at 30 days, 3 months, and 6 months. The primary endpoint is the difference in scar pliability between LED-RL-treated and control sites as determined by skin elasticity and induration measurements. Secondary outcomes include clinical and photographic evaluations of scars, 3D skin imaging analysis, histological and molecular analyses, and adverse events. Discussion LED-RL is a therapeutic modality of increasing importance in dermatology, and has the potential to limit skin fibrosis clinically by decreasing dermal fibroblast activity and collagen production. The administration of LED-RL phototherapy in the early postoperative period may optimize wound healing and prevent excessive scarring. The results from this study may change the current treatment paradigm for fibrotic skin diseases and help to pioneer LED-RL as a safe, non-invasive, cost-effective, portable, at-home therapy for scars. Trial registration ClinicalTrials.gov, NCT03795116. Registered on 20 December 2018. Background Skin fibrosis is a significant global health problem that affects over 100 million people annually and has a profoundly negative impact on quality of life. Characterized by excessive fibroblast proliferation and collagen deposition, skin fibrosis underlies a wide spectrum of dermatologic conditions ranging from pathologic scars secondary to injury (e.g., burns, surgery, trauma) to immune-mediated diseases. Effective anti-scarring therapeutics remain an unmet need, underscoring the importance of developing novel approaches to treat and prevent skin fibrosis. Our in vitro data show that light emitting diode-red light (LED-RL) can modulate key cellular and molecular processes involved in skin fibrosis. In two phase I clinical trials (STARS 1 and STARS 2), we demonstrated the safety and tolerability of LED-RL at fluences of 160 J/cm.sup.2 up to 480 J/cm.sup.2 on normal human skin. Methods/design CURES (Cutaneous Understanding of Red-light Efficacy on Scarring) is a dose-ranging, randomized, parallel group, split-face, single-blind, mock-controlled phase II study to evaluate the efficacy of LED-RL to limit post-surgical skin fibrosis in subjects undergoing elective mini-facelift surgery. Thirty subjects will be randomly allocated to three treatment groups to receive LED-RL phototherapy or temperature-matched mock irradiation (control) to either periauricular incision site at fluences of 160 J/cm.sup.2, 320 J/cm.sup.2, or 480 J/cm.sup.2. Starting one week post-surgery (postoperative days 4-8), treatments will be administered three times weekly for three consecutive weeks, followed by efficacy assessments at 30 days, 3 months, and 6 months. The primary endpoint is the difference in scar pliability between LED-RL-treated and control sites as determined by skin elasticity and induration measurements. Secondary outcomes include clinical and photographic evaluations of scars, 3D skin imaging analysis, histological and molecular analyses, and adverse events. Discussion LED-RL is a therapeutic modality of increasing importance in dermatology, and has the potential to limit skin fibrosis clinically by decreasing dermal fibroblast activity and collagen production. The administration of LED-RL phototherapy in the early postoperative period may optimize wound healing and prevent excessive scarring. The results from this study may change the current treatment paradigm for fibrotic skin diseases and help to pioneer LED-RL as a safe, non-invasive, cost-effective, portable, at-home therapy for scars. Trial registration ClinicalTrials.gov, NCT03795116. Registered on 20 December 2018. Keywords: Light emitting diode, Red light, Phototherapy, Skin fibrosis, Wound healing, Scarring, Hypertrophic scar, Keloid, Surgery Skin fibrosis is a significant global health problem that affects over 100 million people annually and has a profoundly negative impact on quality of life. Characterized by excessive fibroblast proliferation and collagen deposition, skin fibrosis underlies a wide spectrum of dermatologic conditions ranging from pathologic scars secondary to injury (e.g., burns, surgery, trauma) to immune-mediated diseases. Effective anti-scarring therapeutics remain an unmet need, underscoring the importance of developing novel approaches to treat and prevent skin fibrosis. Our in vitro data show that light emitting diode-red light (LED-RL) can modulate key cellular and molecular processes involved in skin fibrosis. In two phase I clinical trials (STARS 1 and STARS 2), we demonstrated the safety and tolerability of LED-RL at fluences of 160 J/cm.sup.2 up to 480 J/cm.sup.2 on normal human skin. CURES (Cutaneous Understanding of Red-light Efficacy on Scarring) is a dose-ranging, randomized, parallel group, split-face, single-blind, mock-controlled phase II study to evaluate the efficacy of LED-RL to limit post-surgical skin fibrosis in subjects undergoing elective mini-facelift surgery. Thirty subjects will be randomly allocated to three treatment groups to receive LED-RL phototherapy or temperature-matched mock irradiation (control) to either periauricular incision site at fluences of 160 J/cm.sup.2, 320 J/cm.sup.2, or 480 J/cm.sup.2. Starting one week post-surgery (postoperative days 4-8), treatments will be administered three times weekly for three consecutive weeks, followed by efficacy assessments at 30 days, 3 months, and 6 months. The primary endpoint is the difference in scar pliability between LED-RL-treated and control sites as determined by skin elasticity and induration measurements. Secondary outcomes include clinical and photographic evaluations of scars, 3D skin imaging analysis, histological and molecular analyses, and adverse events. LED-RL is a therapeutic modality of increasing importance in dermatology, and has the potential to limit skin fibrosis clinically by decreasing dermal fibroblast activity and collagen production. The administration of LED-RL phototherapy in the early postoperative period may optimize wound healing and prevent excessive scarring. The results from this study may change the current treatment paradigm for fibrotic skin diseases and help to pioneer LED-RL as a safe, non-invasive, cost-effective, portable, at-home therapy for scars. Skin fibrosis is a significant global health problem that affects over 100 million people annually and has a profoundly negative impact on quality of life. Characterized by excessive fibroblast proliferation and collagen deposition, skin fibrosis underlies a wide spectrum of dermatologic conditions ranging from pathologic scars secondary to injury (e.g., burns, surgery, trauma) to immune-mediated diseases. Effective anti-scarring therapeutics remain an unmet need, underscoring the importance of developing novel approaches to treat and prevent skin fibrosis. Our in vitro data show that light emitting diode-red light (LED-RL) can modulate key cellular and molecular processes involved in skin fibrosis. In two phase I clinical trials (STARS 1 and STARS 2), we demonstrated the safety and tolerability of LED-RL at fluences of 160 J/cm up to 480 J/cm on normal human skin. CURES (Cutaneous Understanding of Red-light Efficacy on Scarring) is a dose-ranging, randomized, parallel group, split-face, single-blind, mock-controlled phase II study to evaluate the efficacy of LED-RL to limit post-surgical skin fibrosis in subjects undergoing elective mini-facelift surgery. Thirty subjects will be randomly allocated to three treatment groups to receive LED-RL phototherapy or temperature-matched mock irradiation (control) to either periauricular incision site at fluences of 160 J/cm , 320 J/cm , or 480 J/cm . Starting one week post-surgery (postoperative days 4-8), treatments will be administered three times weekly for three consecutive weeks, followed by efficacy assessments at 30 days, 3 months, and 6 months. The primary endpoint is the difference in scar pliability between LED-RL-treated and control sites as determined by skin elasticity and induration measurements. Secondary outcomes include clinical and photographic evaluations of scars, 3D skin imaging analysis, histological and molecular analyses, and adverse events. LED-RL is a therapeutic modality of increasing importance in dermatology, and has the potential to limit skin fibrosis clinically by decreasing dermal fibroblast activity and collagen production. The administration of LED-RL phototherapy in the early postoperative period may optimize wound healing and prevent excessive scarring. The results from this study may change the current treatment paradigm for fibrotic skin diseases and help to pioneer LED-RL as a safe, non-invasive, cost-effective, portable, at-home therapy for scars. ClinicalTrials.gov, NCT03795116 . Registered on 20 December 2018. |
| ArticleNumber | 432 |
| Audience | Academic |
| Author | Siegel, Daniel M. Isseroff, R. Rivkah Weedon, Jeremy Jakus, Jeannette Heilman, Edward Jagdeo, Jared R. Nguyen, Julie K. |
| Author_xml | – sequence: 1 givenname: Julie K. surname: Nguyen fullname: Nguyen, Julie K. organization: Department of Dermatology, SUNY Downstate Health Sciences University, Dermatology Service, VA New York Harbor Healthcare System – sequence: 2 givenname: Jeremy surname: Weedon fullname: Weedon, Jeremy organization: Statistical Design & Analysis Research Division, SUNY Downstate Health Sciences University – sequence: 3 givenname: Jeannette surname: Jakus fullname: Jakus, Jeannette organization: Department of Dermatology, SUNY Downstate Health Sciences University – sequence: 4 givenname: Edward surname: Heilman fullname: Heilman, Edward organization: Department of Dermatology, SUNY Downstate Health Sciences University – sequence: 5 givenname: R. Rivkah surname: Isseroff fullname: Isseroff, R. Rivkah organization: Dermatology Service, Sacramento VA Medical Center, Department of Dermatology, University of California Davis – sequence: 6 givenname: Daniel M. surname: Siegel fullname: Siegel, Daniel M. organization: Department of Dermatology, SUNY Downstate Health Sciences University, Dermatology Service, VA New York Harbor Healthcare System – sequence: 7 givenname: Jared R. surname: Jagdeo fullname: Jagdeo, Jared R. email: jrjagdeo@gmail.com organization: Department of Dermatology, SUNY Downstate Health Sciences University, Dermatology Service, VA New York Harbor Healthcare System |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31307501$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kttqFTEUhgep2IM-gDcS8KZCpyaTSTLjhVBq1Q0bBNHrkMlhmpo9mSazC_XtfDPXdO_aAyq5SEj-_0vWyr9f7AxxsEXxkuBjQhr-NhOKOS0xaUvKal7yJ8UeETUreUXYzr31brGf8wXGNW1p_azYpWAUDJO94tcJMjHbMqmh90N_hEaVVAg2oD7F9XiE8hj8VDqlLaxBEWzZBT8YNJ6rbNFigfK0NtcoOhR8fz4hu_LTBEJkfDQAtmZ7cLg8-1B-Xb5BLiaUf_gBZa1SmqVjsld2mHwc3m1xY4pT1DHciBWC55m48j8BpuMwpQhPNGhKXoXnxVOnQrYvtvNB8f3j2bfTz-Xyy6fF6cmy1BzTqdQdqxuuTcsr5VTXCEU7ZXhrhGOC1ZjamhjFqsYxBW3DTjWV0Y1R3DiqsKMHxWLDNVFdyDH5lUrXMiovbzZi6qVKk9fBytoQ4TpCrcF1jSvRzLfVurGkFg3vBLDeb1jjultZo6F26PoD6MOTwZ_LPl5JzimpmxYAh1tAipdrmye58lnbENRg4zrLqmKNYAQzAtLXj6QXcZ0GaJWsRMsox60Qd6peQQF-cBHu1TNUnjAIDWs4aUB1_BcVDAO_Dh9jnYf9B4ZX9wv9U-FtAEEgNgKdYs7JOqn9pOYkANkHSbCcoy43UZcQdTlHXXJwkkfOW_j_PNXGk8c5dzbd9eLfpt-6YBF- |
| CitedBy_id | crossref_primary_10_1111_srt_13384 crossref_primary_10_1002_jbio_202000359 crossref_primary_10_25289_ML_23_001 crossref_primary_10_1016_j_jphotobiol_2021_112298 crossref_primary_10_1016_j_optlastec_2020_106698 crossref_primary_10_1016_j_jphotochem_2021_113701 crossref_primary_10_3390_biomedicines11092526 crossref_primary_10_3389_fimmu_2022_883239 crossref_primary_10_1016_j_pdpdt_2019_09_006 crossref_primary_10_1016_j_jaad_2020_03_115 crossref_primary_10_1007_s10103_022_03637_6 |
| Cites_doi | 10.1097/DSS.0000000000001549 10.1016/j.jaad.2011.08.035 10.3389/fmed.2017.00083 10.1007/s40257-016-0175-7 10.3390/ijms19030711 10.1038/jid.2011.476 10.1111/j.1600-0781.2010.00539.x 10.1097/01.prs.0000172982.43599.d6 10.1002/jbio.201600059 10.1111/j.1600-0846.2009.00400.x 10.1111/j.1524-475X.2009.00543.x 10.1111/jocd.12690 10.2353/ajpath.2006.051302 10.1097/PRS.0b013e31816a9f6f 10.1007/978-1-84800-165-7_41 10.1097/01.PRS.0000122207.28773.56 10.1136/bmj.326.7380.88 10.1097/01.DSS.0000452650.06765.51 10.1111/ics.12444 10.1111/jocd.12738 10.3109/09638280902874196 10.1007/BF03324769 10.1111/j.1365-2133.2011.10576.x 10.1111/srt.12381 10.1089/lrb.2016.0029 10.1089/wound.2015.0646 10.1016/j.bjps.2008.03.020 10.1016/j.jaad.2015.02.003 10.1016/j.pdpdt.2010.07.003 10.1097/DSS.0000000000000283 10.1159/000342344 10.1111/srt.12199 10.1111/j.1524-475X.2010.00607.x 10.1016/S0901-5027(05)80377-7 10.1111/ijd.12436 10.1111/dsu.12212 10.1093/asj/sjv162 10.1111/jdv.13805 10.1002/lsm.22707 10.1002/lsm.22791 10.1111/bjd.12277 10.1089/wound.2016.0709 10.1111/srt.12125 10.5999/aps.2014.41.2.111 10.1016/j.jaad.2009.11.032 10.1001/archderm.1990.01670290105019 10.1371/journal.pone.0047460 10.1007/s10439-011-0454-7 10.1097/01.prs.0000232378.88776.b0 10.1111/jdv.14856 10.1097/PRS.0000000000000417 10.1111/j.1751-1097.2007.00286.x 10.1046/j.1365-2133.1998.02403.x 10.1097/00006534-200004050-00001 10.1097/01.prs.0000252949.77525.bc 10.1111/j.1067-1927.2005.130211.x 10.1186/s13063-015-1128-9 10.1001/jamadermatol.2016.5232 10.1159/000330721 10.3346/jkms.2014.29.6.751 10.1007/s00403-006-0651-7 10.1111/j.1473-2165.2008.00404.x 10.1111/srt.12455 10.1038/nm.2807 10.2203/dose-response.11-009.Hamblin 10.1097/PRS.0000000000000972 10.1089/wound.2016.0696 10.1002/path.2277 |
| ContentType | Journal Article |
| Copyright | The Author(s). 2019 COPYRIGHT 2019 BioMed Central Ltd. The Author(s). 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s). 2019 – notice: COPYRIGHT 2019 BioMed Central Ltd. – notice: The Author(s). 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7RV 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. KB0 M0S M1P NAPCQ PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s13063-019-3546-6 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Health & Medical Collection Medical Database Nursing & Allied Health Premium Proquest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database MEDLINE |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1745-6215 |
| EndPage | 10 |
| ExternalDocumentID | oai_doaj_org_article_4d17fb13ed044027887a34c8e14786b7 PMC6631489 A593458618 31307501 10_1186_s13063_019_3546_6 |
| Genre | Clinical Trial Protocol Journal Article |
| GeographicLocations | New York United States--US |
| GeographicLocations_xml | – name: New York – name: United States--US |
| GrantInformation_xml | – fundername: National Institute of General Medical Sciences grantid: K23GM117309 funderid: http://dx.doi.org/10.13039/100000057 – fundername: National Institute of General Medical Sciences grantid: K23GM117309 – fundername: ; grantid: K23GM117309 |
| GroupedDBID | --- 0R~ 123 2-G 29Q 2WC 53G 5VS 6PF 7RV 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABUWG ACGFO ACGFS ACUHS ADBBV ADRAZ ADUKV AEGXH AENEX AFKRA AFPKN AHBYD AHYZX AIAGR ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC C6C CCPQU CS3 DIK DU5 E3Z EBD EBLON EBS EJD EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 M~E NAPCQ O5R O5S OVT PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PSQYO PUEGO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS U2A UKHRP WOQ WOW ~8M AAYXX ALIPV CITATION -5E -5G -A0 -BR ACRMQ ADINQ C24 CGR CUY CVF ECM EIF NPM PMFND 3V. 5GY 7XB 8FK AHMBA AZQEC DWQXO K9. PKEHL PQEST PQQKQ PQUKI PRINS XSB 7X8 5PM |
| ID | FETCH-LOGICAL-c603t-cb5486cd962afab87a3bad69d7f575403e41da528f5a7450fa82dc8da6df3a0f3 |
| IEDL.DBID | M48 |
| ISSN | 1745-6215 |
| IngestDate | Wed Aug 27 01:32:42 EDT 2025 Thu Aug 21 17:56:52 EDT 2025 Thu Sep 04 15:57:49 EDT 2025 Fri Jul 25 08:45:41 EDT 2025 Tue Jun 17 21:09:33 EDT 2025 Tue Jun 10 20:48:34 EDT 2025 Thu Jan 02 22:59:23 EST 2025 Tue Jul 01 04:00:36 EDT 2025 Thu Apr 24 23:02:18 EDT 2025 Sat Sep 06 07:26:46 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Wound healing Skin fibrosis Keloid Surgery Red light Hypertrophic scar Scarring Light emitting diode Phototherapy |
| Language | English |
| License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c603t-cb5486cd962afab87a3bad69d7f575403e41da528f5a7450fa82dc8da6df3a0f3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-3 ObjectType-Evidence Based Healthcare-1 ObjectType-Undefined-1 content type line 23 |
| OpenAccessLink | https://link.springer.com/10.1186/s13063-019-3546-6 |
| PMID | 31307501 |
| PQID | 2795360977 |
| PQPubID | 44365 |
| PageCount | 10 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_4d17fb13ed044027887a34c8e14786b7 pubmedcentral_primary_oai_pubmedcentral_nih_gov_6631489 proquest_miscellaneous_2258751051 proquest_journals_2795360977 gale_infotracmisc_A593458618 gale_infotracacademiconefile_A593458618 pubmed_primary_31307501 crossref_citationtrail_10_1186_s13063_019_3546_6 crossref_primary_10_1186_s13063_019_3546_6 springer_journals_10_1186_s13063_019_3546_6 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2019-07-15 |
| PublicationDateYYYYMMDD | 2019-07-15 |
| PublicationDate_xml | – month: 07 year: 2019 text: 2019-07-15 day: 15 |
| PublicationDecade | 2010 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Current controlled trials in cardiovascular medicine |
| PublicationTitleAbbrev | Trials |
| PublicationTitleAlternate | Trials |
| PublicationYear | 2019 |
| Publisher | BioMed Central BioMed Central Ltd BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: BMC |
| References | 3546_CR73 TA Wynn (3546_CR1) 2009; 214 JAL Duncan (3546_CR57) 2006; 118 MH Gold (3546_CR13) 2014; 40 O Bock (3546_CR9) 2006; 297 H Lee (3546_CR6) 2018; 19 V Gupta (3546_CR77) 2015; 36 CK Sen (3546_CR11) 2010; 17 NS Sadick (3546_CR37) 2008; 7 Photo Therapeutics Inc (3546_CR44) 2009 3546_CR78 JR Marcus (3546_CR84) 2000; 105 A Mamalis (3546_CR30) 2018; 44 BH Mahmoud (3546_CR16) 2008; 84 KL Anderson (3546_CR40) 2015; 72 NJ Wainwright (3546_CR38) 1998; 139 D Son (3546_CR66) 2014; 29 TA Wynn (3546_CR2) 2012; 18 MA Kim (3546_CR46) 2018; 24 L Cuttle (3546_CR62) 2005; 13 DW Thomas (3546_CR81) 1994; 23 JS Bond (3546_CR83) 2008; 121 JA Bush (3546_CR8) 2011; 19 R Sgonc (3546_CR82) 2013; 59 IG Luzina (3546_CR4) 2008 Food and Drug Administration (3546_CR63) 2018 LA Barnes (3546_CR70) 2018; 7 MH Gold (3546_CR86) 2014; 40 CV Wa (3546_CR75) 2010; 16 F Linming (3546_CR60) 2018; 24 JT Iivarinen (3546_CR48) 2014; 20 SH Bae (3546_CR54) 2014; 41 PT Truong (3546_CR52) 2007; 119 D Ho (3546_CR32) 2016; 17 X Liu (3546_CR55) 2017; 31 KE Karmisholt (3546_CR71) 2018; 32 FH Sakamoto (3546_CR27) 2012; 166 Food and Drug Administration (3546_CR41) 2008 SM Campbell (3546_CR25) 2010; 7 ZB Mokos (3546_CR85) 2017; 4 GG Walmsley (3546_CR14) 2015; 135 J Jagdeo (3546_CR19) 2018; 50 F Liebel (3546_CR15) 2012; 132 L Block (3546_CR67) 2015; 4 DR Opel (3546_CR18) 2015; 8 LY Kerwin (3546_CR68) 2014; 53 A Bayat (3546_CR7) 2003; 326 MT Longaker (3546_CR35) 2014; 134 3546_CR59 CD Marshall (3546_CR69) 2018; 7 C Tziotzios (3546_CR12) 2012; 66 AL Van De Kar (3546_CR51) 2005; 116 G Ablon (3546_CR20) 2018; 11 JR Jagdeo (3546_CR24) 2012; 7 AP Trace (3546_CR5) 2016; 17 R Fearmonti (3546_CR49) 2010; 10 DC Micomonaco (3546_CR56) 2009; 38 Photo Therapeutics Inc (3546_CR33) 2008 PG Calzavara-Pinton (3546_CR39) 2013; 169 KE Karmisholt (3546_CR72) 2018; 50 J Uitto (3546_CR3) 1990; 126 A Mamalis (3546_CR29) 2015; 41 T Virén (3546_CR47) 2018; 40 Y-Y Huang (3546_CR43) 2011; 9 J Varani (3546_CR80) 2006; 168 A Mamalis (3546_CR31) 2016; 9 P Kleesz (3546_CR76) 2011; 25 BC Brown (3546_CR10) 2008; 61 NS Sadick (3546_CR36) 2008; 7 MA Farage (3546_CR79) 2008; 20 3546_CR21 Food and Drug Administration (3546_CR42) 2009 3546_CR23 Photo Therapeutics Inc (3546_CR34) 2009 J Jagdeo (3546_CR65) 2017; 153 MT Hession (3546_CR22) 2015; 41 Z Nie (3546_CR26) 2010; 26 H Lev-Tov (3546_CR28) 2013; 39 LJ Draaijers (3546_CR53) 2004; 113 ST Butler (3546_CR74) 2010; 63 D Sun (3546_CR45) 2017; 15 H Chung (3546_CR17) 2012; 40 S Vercelli (3546_CR50) 2009; 25 T Nappez (3546_CR58) 2018 AR Matias (3546_CR61) 2015; 21 G Urbaniak (3546_CR64) 2013 |
| References_xml | – volume: 44 start-page: 1317 issue: 10 year: 2018 ident: 3546_CR30 publication-title: Dermatol Surg doi: 10.1097/DSS.0000000000001549 – volume: 66 start-page: 13 issue: 1 year: 2012 ident: 3546_CR12 publication-title: J Am Acad Dermatol doi: 10.1016/j.jaad.2011.08.035 – volume: 4 start-page: 1 year: 2017 ident: 3546_CR85 publication-title: Front Med doi: 10.3389/fmed.2017.00083 – volume: 17 start-page: 201 issue: 3 year: 2016 ident: 3546_CR5 publication-title: Am J Clin Dermatol doi: 10.1007/s40257-016-0175-7 – volume: 19 start-page: 711 issue: 3 year: 2018 ident: 3546_CR6 publication-title: Int J Mol Sci doi: 10.3390/ijms19030711 – volume: 132 start-page: 1901 issue: 7 year: 2012 ident: 3546_CR15 publication-title: J Invest Dermatol doi: 10.1038/jid.2011.476 – volume: 26 start-page: 330 issue: 6 year: 2010 ident: 3546_CR26 publication-title: Photodermatol Photoimmunol Photomed doi: 10.1111/j.1600-0781.2010.00539.x – volume: 116 start-page: 514 issue: 2 year: 2005 ident: 3546_CR51 publication-title: Plast Reconstr Surg doi: 10.1097/01.prs.0000172982.43599.d6 – volume: 9 start-page: 1167 issue: 11–12 year: 2016 ident: 3546_CR31 publication-title: J Biophotonics doi: 10.1002/jbio.201600059 – volume-title: 510(k) Summary of safety and effectiveness for the Photo Therapeutics Limited Omnilux New-U year: 2008 ident: 3546_CR41 – volume: 16 start-page: 38 issue: 1 year: 2010 ident: 3546_CR75 publication-title: Skin Res Technol doi: 10.1111/j.1600-0846.2009.00400.x – volume: 17 start-page: 763 issue: 6 year: 2010 ident: 3546_CR11 publication-title: Wound Repair Regen doi: 10.1111/j.1524-475X.2009.00543.x – ident: 3546_CR73 doi: 10.1111/jocd.12690 – volume-title: Development and validation of a non-invasive spatially resolved spectroscopy probe for collagen and water determination year: 2018 ident: 3546_CR58 – ident: 3546_CR23 – volume: 168 start-page: 1861 issue: 6 year: 2006 ident: 3546_CR80 publication-title: Am J Pathol doi: 10.2353/ajpath.2006.051302 – volume: 121 start-page: 1650 issue: 5 year: 2008 ident: 3546_CR83 publication-title: Plast Reconstr Surg doi: 10.1097/PRS.0b013e31816a9f6f – start-page: 721 volume-title: Clinical and basic immunodermatology year: 2008 ident: 3546_CR4 doi: 10.1007/978-1-84800-165-7_41 – volume-title: 510(k) Summary of safety and effectiveness for the Photo Therapeutics Limited Omnilux Plus year: 2009 ident: 3546_CR42 – volume: 113 start-page: 1960 issue: 7 year: 2004 ident: 3546_CR53 publication-title: Plast Reconstr Surg doi: 10.1097/01.PRS.0000122207.28773.56 – volume: 326 start-page: 88 issue: 7380 year: 2003 ident: 3546_CR7 publication-title: BMJ doi: 10.1136/bmj.326.7380.88 – volume-title: Research randomizer year: 2013 ident: 3546_CR64 – volume: 41 start-page: 35 issue: 1 year: 2015 ident: 3546_CR29 publication-title: Dermatol Surg doi: 10.1097/01.DSS.0000452650.06765.51 – volume: 40 start-page: 134 issue: 2 year: 2018 ident: 3546_CR47 publication-title: Int J Cosmet Sci doi: 10.1111/ics.12444 – ident: 3546_CR59 doi: 10.1111/jocd.12738 – volume-title: Code of federal regulations: Investigational new drug application, 21 CFR 312.32 year: 2018 ident: 3546_CR63 – volume: 25 start-page: 2055 issue: 31 year: 2009 ident: 3546_CR50 publication-title: Disabil Rehabil doi: 10.3109/09638280902874196 – volume: 20 start-page: 195 issue: 3 year: 2008 ident: 3546_CR79 publication-title: Aging Clin Exp Res doi: 10.1007/BF03324769 – volume: 7 start-page: 347 issue: 4 year: 2008 ident: 3546_CR37 publication-title: J Drugs Dermatol – volume: 166 start-page: 413 issue: 2 year: 2012 ident: 3546_CR27 publication-title: Br J Dermatol doi: 10.1111/j.1365-2133.2011.10576.x – volume: 24 start-page: 3 issue: 1 year: 2018 ident: 3546_CR60 publication-title: Skin Res Technol doi: 10.1111/srt.12381 – volume: 15 start-page: 70 issue: 1 year: 2017 ident: 3546_CR45 publication-title: Lymphat Res Biol doi: 10.1089/lrb.2016.0029 – volume: 4 start-page: 607 issue: 10 year: 2015 ident: 3546_CR67 publication-title: Adv Wound Care doi: 10.1089/wound.2015.0646 – volume: 61 start-page: 1049 issue: 9 year: 2008 ident: 3546_CR10 publication-title: J Plast Reconstr Aesthetic Surg doi: 10.1016/j.bjps.2008.03.020 – volume: 72 start-page: 868 issue: 5 year: 2015 ident: 3546_CR40 publication-title: J Am Acad Dermatol doi: 10.1016/j.jaad.2015.02.003 – start-page: 1 volume-title: Omnilux medical treatment protocols year: 2009 ident: 3546_CR44 – volume: 7 start-page: 183 issue: 3 year: 2010 ident: 3546_CR25 publication-title: Photodiagn Photodyn Ther doi: 10.1016/j.pdpdt.2010.07.003 – volume: 41 start-page: 307 issue: 3 year: 2015 ident: 3546_CR22 publication-title: Dermatol Surg doi: 10.1097/DSS.0000000000000283 – volume: 59 start-page: 159 issue: 2 year: 2013 ident: 3546_CR82 publication-title: Gerontology doi: 10.1159/000342344 – volume: 21 start-page: 346 issue: 3 year: 2015 ident: 3546_CR61 publication-title: Skin Res Technol doi: 10.1111/srt.12199 – volume: 19 start-page: s32 issue: SUPPL. 1 year: 2011 ident: 3546_CR8 publication-title: Wound Repair Regen doi: 10.1111/j.1524-475X.2010.00607.x – volume: 23 start-page: 232 issue: 4 year: 1994 ident: 3546_CR81 publication-title: Int J Oral Maxillofac Surg doi: 10.1016/S0901-5027(05)80377-7 – volume: 11 start-page: 21 issue: 2 year: 2018 ident: 3546_CR20 publication-title: J Clin Aesthet Dermatol – volume: 53 start-page: 922 issue: 8 year: 2014 ident: 3546_CR68 publication-title: Int J Dermatol doi: 10.1111/ijd.12436 – volume: 40 start-page: 817 issue: 8 year: 2014 ident: 3546_CR13 publication-title: Dermatol Surg – volume: 39 start-page: 1167 issue: 8 year: 2013 ident: 3546_CR28 publication-title: Dermatol Surg doi: 10.1111/dsu.12212 – start-page: 1 volume-title: Omnilux clear-U user guide year: 2009 ident: 3546_CR34 – volume: 36 start-page: 1 issue: 1 year: 2015 ident: 3546_CR77 publication-title: Aesthetic Surg J doi: 10.1093/asj/sjv162 – volume: 31 start-page: 341 issue: 2 year: 2017 ident: 3546_CR55 publication-title: J Eur Acad Dermatol Venereol doi: 10.1111/jdv.13805 – volume: 50 start-page: 28 issue: 1 year: 2018 ident: 3546_CR72 publication-title: Lasers Surg Med doi: 10.1002/lsm.22707 – volume: 50 start-page: 613 issue: 6 year: 2018 ident: 3546_CR19 publication-title: Lasers Surg Med doi: 10.1002/lsm.22791 – volume: 169 start-page: 130 issue: 1 year: 2013 ident: 3546_CR39 publication-title: Br J Dermatol doi: 10.1111/bjd.12277 – volume: 7 start-page: 47 issue: 2 year: 2018 ident: 3546_CR70 publication-title: Adv Wound Care doi: 10.1089/wound.2016.0709 – volume: 20 start-page: 347 issue: 3 year: 2014 ident: 3546_CR48 publication-title: Skin Res Technol doi: 10.1111/srt.12125 – volume: 41 start-page: 111 issue: 2 year: 2014 ident: 3546_CR54 publication-title: Arch Plast Surg doi: 10.5999/aps.2014.41.2.111 – volume: 63 start-page: 1006 issue: 6 year: 2010 ident: 3546_CR74 publication-title: J Am Acad Dermatol doi: 10.1016/j.jaad.2009.11.032 – volume: 126 start-page: 661 issue: 5 year: 1990 ident: 3546_CR3 publication-title: Arch Dermatol doi: 10.1001/archderm.1990.01670290105019 – volume: 7 start-page: 1 issue: 10 year: 2012 ident: 3546_CR24 publication-title: PLoS One doi: 10.1371/journal.pone.0047460 – volume: 40 start-page: 825 issue: 8 year: 2014 ident: 3546_CR86 publication-title: Dermatol Surg – volume: 40 start-page: 516 issue: 2 year: 2012 ident: 3546_CR17 publication-title: Ann Biomed Eng doi: 10.1007/s10439-011-0454-7 – ident: 3546_CR21 – volume: 38 start-page: 77 issue: 1 year: 2009 ident: 3546_CR56 publication-title: J Otolaryngol Head Neck Surg – volume: 118 start-page: 909 issue: 4 year: 2006 ident: 3546_CR57 publication-title: Plast Reconstr Surg doi: 10.1097/01.prs.0000232378.88776.b0 – volume: 32 start-page: 1099 issue: 7 year: 2018 ident: 3546_CR71 publication-title: J Eur Acad Dermatol Venereol doi: 10.1111/jdv.14856 – volume: 134 start-page: 536 issue: 3 year: 2014 ident: 3546_CR35 publication-title: Plast Reconstr Surg doi: 10.1097/PRS.0000000000000417 – volume: 84 start-page: 450 issue: 2 year: 2008 ident: 3546_CR16 publication-title: Photochem Photobiol doi: 10.1111/j.1751-1097.2007.00286.x – volume: 139 start-page: 410 issue: 3 year: 1998 ident: 3546_CR38 publication-title: Br J Dermatol doi: 10.1046/j.1365-2133.1998.02403.x – volume: 105 start-page: 1591 issue: 5 year: 2000 ident: 3546_CR84 publication-title: Plast Reconstr Surg doi: 10.1097/00006534-200004050-00001 – volume: 119 start-page: 487 issue: 2 year: 2007 ident: 3546_CR52 publication-title: Plast Reconstr Surg doi: 10.1097/01.prs.0000252949.77525.bc – volume: 13 start-page: 198 issue: 2 year: 2005 ident: 3546_CR62 publication-title: Wound Repair Regen doi: 10.1111/j.1067-1927.2005.130211.x – volume: 17 start-page: 1 issue: 1 year: 2016 ident: 3546_CR32 publication-title: Trials doi: 10.1186/s13063-015-1128-9 – volume: 153 start-page: 364 issue: 3 year: 2017 ident: 3546_CR65 publication-title: JAMA Dermatol doi: 10.1001/jamadermatol.2016.5232 – volume: 25 start-page: 25 issue: 1 year: 2011 ident: 3546_CR76 publication-title: Skin Pharmacol Physiol doi: 10.1159/000330721 – volume: 29 start-page: 751 issue: 6 year: 2014 ident: 3546_CR66 publication-title: J Korean Med Sci doi: 10.3346/jkms.2014.29.6.751 – volume: 10 start-page: e43 year: 2010 ident: 3546_CR49 publication-title: J Plast Surg – volume: 297 start-page: 433 issue: 10 year: 2006 ident: 3546_CR9 publication-title: Arch Dermatol Res doi: 10.1007/s00403-006-0651-7 – volume: 8 start-page: 36 issue: 6 year: 2015 ident: 3546_CR18 publication-title: J Clin Aesthet Dermatol – volume: 7 start-page: 263 issue: 4 year: 2008 ident: 3546_CR36 publication-title: J Cosmet Dermatol doi: 10.1111/j.1473-2165.2008.00404.x – volume: 24 start-page: 466 issue: 3 year: 2018 ident: 3546_CR46 publication-title: Skin Res Technol doi: 10.1111/srt.12455 – volume: 18 start-page: 1028 issue: 7 year: 2012 ident: 3546_CR2 publication-title: Nat Med doi: 10.1038/nm.2807 – start-page: 1 volume-title: Omnilux new-U user guide year: 2008 ident: 3546_CR33 – volume: 9 start-page: 602 issue: 4 year: 2011 ident: 3546_CR43 publication-title: Dose Response doi: 10.2203/dose-response.11-009.Hamblin – ident: 3546_CR78 – volume: 135 start-page: 907 issue: 3 year: 2015 ident: 3546_CR14 publication-title: Plast Reconstr Surg doi: 10.1097/PRS.0000000000000972 – volume: 7 start-page: 29 issue: 2 year: 2018 ident: 3546_CR69 publication-title: Adv Wound Care doi: 10.1089/wound.2016.0696 – volume: 214 start-page: 199 issue: 2 year: 2009 ident: 3546_CR1 publication-title: J Pathol doi: 10.1002/path.2277 |
| SSID | ssj0043934 ssj0017864 |
| Score | 2.2666852 |
| Snippet | Background
Skin fibrosis is a significant global health problem that affects over 100 million people annually and has a profoundly negative impact on quality... Skin fibrosis is a significant global health problem that affects over 100 million people annually and has a profoundly negative impact on quality of life.... Background Skin fibrosis is a significant global health problem that affects over 100 million people annually and has a profoundly negative impact on quality... BackgroundSkin fibrosis is a significant global health problem that affects over 100 million people annually and has a profoundly negative impact on quality of... Abstract Background Skin fibrosis is a significant global health problem that affects over 100 million people annually and has a profoundly negative impact on... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 432 |
| SubjectTerms | Acne Analysis Biomedicine Care and treatment Cicatrices Cicatrix - etiology Cicatrix - pathology Cicatrix - prevention & control Clinical trials Clinical Trials, Phase II as Topic Collagen Electronic components Erythema Face lifts Fibroblasts Fibrosis Health Health Sciences Humans Influence LEDs Light emitting diode Light emitting diodes Light therapy Medicine Medicine & Public Health New York Phototherapy Phototherapy - adverse effects Phototherapy - methods Postoperative Care - adverse effects Postoperative Care - methods Prevention Quality of life Radiation Dosage Randomized Controlled Trials as Topic Red light Scarring Scars Single-Blind Method Skin Skin - pathology Skin - radiation effects Skin diseases Skin fibrosis Statistics for Life Sciences Study Protocol Surgery Therapeutics Time Factors Treatment Outcome World health Wound care Wound healing Wounds |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Jb9UwELZQD4gLYielRUZCYqvVJF7icHtAqxa1HBCVerMcL-oTafLUvF74d_1njB2_R1MEXLhF8djyMp5FM_4GoZfOUk9pWYfiLpQwJwTRnoKrYozUBatyF-GLj7-IgxP2-ZSfXiv1FXLCRnjgceN2mS0q3xTU2VAcuQzJb5oyIx0MJEUT35Hndb5ypkYZDFqWshTDLKTYHUBSh3hlURPKmSBiooUiWP_vIvmaTrqZL3kjaBp10f49dDcZkXg2Tv4-uuW6B-j2cQqTP0RXM2z7wRHQQ6EG0Q4OAN9t61ocH3Hs4AFMzyXx2jj4BorWkQbsTYsXZ6DV8OEhjrCzuPe4Dd47dufzmCCN7by3MLCzqeH10d4n8vXoDQbjFw_f5x0ejL4I08aLhA7Vd-_TcAEUogfOi8Qaw_Rsfz7_AYOljPkWPmMdkUfoZH_v28cDkmo1ECNyuiSmAddHGFuLUnvdhENqtBW1rTwYhCynjhVW81J6rivGc69laY20WlhPde7pY7TR9Z17irBsaldwD55fqVnp65pXtBG6sQzkhdA-Q_nq7JRJQOahnkarokMjhRqPW8Fxq3DcSmTo7brLYkTx-Bvxh8AQa8IAwB1_AFuqxJbqX2yZoVeBnVQQEzA5o9NrB1hiANxSMw4cyqUoZIa2JpRwvc20ecWQKomXQZVViLrnYLtn6MW6OfQMKXOd6y-BpuTgi4L5XGToyci_6yVRWDOYitBSTTh7suZpSzc_i-DjYKGCB11n6N3qDvya1h-3dPN_bOkzdKfM45M7UvAttLG8uHTbYBEum-fx8v8E_J9cQw priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagSIgL4t1AQUZC4lWrcew4Dhe0QKsWtRwQlXqzHD_oijRZNtsL_45_xtjr3ZIieovWE8uzMx7PZMbfIPTCWeYZK-rQ3IUR7oQg2jMIVYyRmvIqdxG--OiL2D_mn0_Kk_TBbUhllSubGA217U34Rr5TVCHRmIO78n72k4SuUSG7mlpoXEc3InQZ6HN1sg64aCUFT5lMKsXOAPY6ZC1pTVjJBRGjsyhC9v9rmP86mS5XTV5KncYTae8Oup1cSTxZyv4uuua6e-jmUUqW30e_J9j2gyNwGoVORNs4wHy3rWtxvMqxjQdwQBfEa-PgGShaRxrwOi2encLZhg8OcASfxb3HbYjhsTubxjJpbKe9hYmdTQOvDnc_ka-HrzG4wHj4Me3wYPQ8LBvPEkZU371L0wVoiB70LxJrDMuz_dn0F0yW6uZbeIzdRB6g473dbx_3SerYQIzI2YKYBgIgYWwtCu11IyvNGm1FbSsPbiHPmePU6rKQvtQVL3OvZWGNtFpYz3Tu2UO00fWd20RYNrWjpYf4r9C88HVdVqwRurEcrIbQPkP5SnbKJDjz0FWjVTGskUItxa1A3CqIW4kMvVm_MltieVxF_CEoxJowwHDHH_r5d5V2teKWVr6hzNnQubsIlZmacSMdaLkUTZWhl0GdVDAWsDij050HYDHAbqlJWTNeSkFlhrZGlLDJzXh4pZAqGZlBXWyJDD1fD4c3Q-Fc5_pzoClKiEjBiaYZerTU3zVLDHgGhxFGqpFmj3gej3TT0whBDn4qxNF1ht6u9sDFsv77lz6-mokn6FaRxyt1hJZbaGMxP3dPweNbNM_itv4DPuJU3A priority: 102 providerName: ProQuest – databaseName: SpringerLink Journals (ICM) dbid: U2A link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Jb9QwFLagSIgLYidQkJGQ2GqRxEscbgO0alHLATFSb5bjhY5Ik2oyvfDv-Gc8e5yBlEXiFsXPkR2_Ve_5ewg9dZZ6Sss6NHehhDkhiPYUQhVjpC5YlbsIX3z0UezP2YdjfpzucQ9jtfuYkoyaOoq1FK8H0LYh51jUhHImiLiMrnAI3YM0zsvZqH7BwFKW0pd_nDYxQBGn_3dt_Is5ulgqeSFfGs3Q3g10PfmPeLY-8JvokutuoatHKUN-G32fYdsPjoAJCu2HdnDA9m5b1-J4f2MHD-B1rojXxsEzULSONPA7LD47AYOGDw5wRJzFvcdtCNyxO13E2mhsF72FDzubBp4f7r4nnw5fYPB78fB10eHB6GVYNj5LwFB99yZ9LuBB9MB0kVhjWJ7tTxff4GOpWL6Fx9hC5A6a7-1-frdPUpsGYkROV8Q0EPUIY2tRaq8bWWnaaCtqW3nwBVlOHSus5qX0XFeM517L0hpptbCe6tzTu2ir6zt3H2HZ1K7gHoK-UrPS1zWvaCN0YxmoCqF9hvLx7JRJGOahlUarYiwjhVoft4LjVuG4lcjQy82UszWAx7-I3waG2BAG7O34ol9-UUmUFbNF5ZuCOhvadZehHFNTZqQD1paiqTL0LLCTChoCFmd0uugAWwxYW2rGgUO5FIXM0PaEEiTbTIdHhlRJswyqrELCPQe3PUNPNsNhZqiW61x_DjQlhzAUPOciQ_fW_LvZEoU9g5cII9WEsyd7no50i5OIOw7OKQTPdYZejTLwc1l__aUP_ov6IbpW5vFaHSn4NtpaLc_dI_D6Vs3jKOU_AC74UVY priority: 102 providerName: Springer Nature |
| Title | A dose-ranging, parallel group, split-face, single-blind phase II study of light emitting diode-red light (LED-RL) for skin scarring prevention: study protocol for a randomized controlled trial |
| URI | https://link.springer.com/article/10.1186/s13063-019-3546-6 https://www.ncbi.nlm.nih.gov/pubmed/31307501 https://www.proquest.com/docview/2795360977 https://www.proquest.com/docview/2258751051 https://pubmed.ncbi.nlm.nih.gov/PMC6631489 https://doaj.org/article/4d17fb13ed044027887a34c8e14786b7 |
| Volume | 20 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3rb9MwELf2kBBfEG8CozISEq8ZkjhxEiSEstKxVduExir1W-T4wSqypDSdBPx3_GecXbeQMZD4kkTxxfLjzneXs3-H0GMlqaY0zExyF0oixRjhmoKrIkTKgyjxlYUvPjxie6NoOI7Ha2iZ3soNYHupa2fySY1m1cuvX769BYF_YwU-Za9aWIdNNDLICI0jRtg62gTFxIwvdhitggqgehdB5iSKCQNV54Kcl1bRUVMWzf_PNfs3pXVxQ-WFqKpVVrvX0TVnZeJ8wRY30Jqqb6Irhy6Ofgv9yLFsWkVAUZkkRdvYIIBXlaqwPeWxjVuwTedEc6HgGSgqRUowSCWenoLaw_v72OLS4kbjyrj3WJ1N7A5qLCeNhIqVdAVPDwbvyPHBMwzWMW4_T2rcCj4zzcZTBx_V1K9ddQY1ogHWtMQcQ_Nkczb5DpW5LfUVPNpEI7fRaHdw0t8jLpkDEcyncyJK8I2YkBkLueZlmnBacskymWiwGCOfqiiQPA5THXOYIF_zNJQilZxJTbmv6R20UTe1uodwWmYqiDW4hiGPQp1lcUJLxksZwYLCuPaQv5y7Qjikc5Nwoyqsx5OyYjHdBUx3Yaa7YB56vvpkuoD5-BfxjmGIFaFB6LYvmtmnwgl8Eckg0WVAlTRJvUOzaZPTSKQKBCBlZeKhJ4adCsPZ0DjB3XEI6KJB5CryGLg1TlmQemirQwnyL7rFS4YsluJThIkJy_tg3Hvo0arYfGn21NWqOQeaMAZnFezrwEN3F_y76hKFPoMtCSVJh7M7fe6W1JNTi04OJiy42JmHXixl4Fez_jqk9_9n_B-gq6Fvz96RIN5CG_PZuXoIpuG87KH1ZJz00GaeDz8O4b4zOPpwDG_7rN-zv1vg-n4c9OzCANdRmP8E215k8A |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1fTxQxEG8QEvXF-N9V1JpoVKRhd9vtdk2MAYFwchBDIOGtdvtHLi67J3vE6IfyO_jNnPb2Dg8jb7xtrrNNezOd-c3OdAah59ZQR2la-OYulDDLOVGOgquitVAJy2Mbyhfv7PKtA_bxMDucQ78md2F8WuVEJwZFbRrtv5GvpLkPNMYAV94PvxHfNcpHVyctNMZisW1_fAeXrX3XWwf-vkjTzY39D1uk6ypANI_piOgSQDrXpuCpcqoUuaKlMrwwuQPowmJqWWJUlgqXqZxlsVMiNVoYxY2jKnYU5r2CFpi_0TqPFtY2dj_tTeMWueCsi50mgq-0YCF8nDQpCM0YJ3zG-oUmAf-agr9s4fk8zXPB2mADN2-iGx14xatjabuF5mx9G13d6cLzd9DvVWya1hKwf7730TL2hcWrylY4XB5Zxi1A3hFxSlt4BorKkhJwrsHDI7CmuNfDodwtbhyu_FcDbI8HITEbm0FjYGJruoFX_Y11std_jQF04_broMatVid-2XjYVaVq6rfddL4YRQMSH4gVhuWZ5njwEybrMvUreAz9S-6ig0vh5j00Xze1fYCwKAubZA48zlSx1BVFltOSq9Iw0FNcuQjFE95J3RVQ9308KhkcKcHlmN0S2C09uyWP0NL0leG4eshFxGteIKaEvvB3-KE5-SI7PSKZSXJXJtQa3ys89bmgijItLJwrwcs8Qi-9OEmvnmBxWnW3LGCLvtCXXM0KyjLBExGhxRlKUCt6dngikLJTa608O4QRejYd9m_6VL3aNqdAk2bgAwNsTyJ0fyy_0y1R2DNAVBjJZyR7Zs-zI_XgKBQ9B2QMnnsRoTeTM3C2rP_-pQ8v3sRTdG1rf6cv-73d7UfoehqHC30kyRbR_Ojk1D4GvDkqn3SHHKPPl61X_gB7HZTT |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKkSouiDeBAkYC8arVJHYcBwmhQlt16UMIUak34_hBV6TJ0myF4Kdx458x9nq3bBHceovWE8veGc98kxnPIPTIGuoozSvf3IUSZjknylFwVbQWKmNlakP54t09vrXP3h0UBwvo5_QujE-rnOrEoKhNp_038tW89IHGFODKqotpEe_XN1-PvhLfQcpHWqftNCYism2_fwP3rX81WAdeP87zzY2Pb7dI7DBANE_pmOgaADvXpuK5cqoWpaK1MrwypQMYw1JqWWZUkQtXqJIVqVMiN1oYxY2jKnUU5r2ALpYUUBWcpfJg5uxlpeAsRlEzwVd7sBU-YppVhBaMEz5nB0O7gL-Nwh9W8WzG5pmwbbCGm1fQ5Qhj8dpE7q6iBdteQ0u7MVB_Hf1aw6brLQFL6LsgrWBfYrxpbIPDNZIV3AP4HROntIVnoGgsqQHxGjw6BLuKBwMcCt_izuHGfz_A9mgYUrSxGXYGJrYmDjzd2VgnH3aeYYDfuP8ybHGv1bFfNh7F-lRd-zJO58tSdCD7gVhhWJ7pjoY_YLKYs9_AY-hkcgPtnwsvb6LFtmvtbYRFXdmscOB75orlrqqKktZc1YaBxuLKJSid8k7qWErdd_RoZHCpBJcTdktgt_TsljxBz2evjCZ1RP5H_MYLxIzQlwAPP3THn2XUKJKZrHR1Rq3xXcNznxWqKNPCwgkTvC4T9MSLk_SKChanVbxvAVv0Jb_kWlFRVgieiQQtz1GCgtHzw1OBlFHB9fL0OCbo4WzYv-mT9lrbnQBNXoA3DAA-S9CtifzOtkRhzwBWYaSck-y5Pc-PtMPDUP4cMDL48FWCXkzPwOmy_vmX3vn_Jh6gJdAmcmewt30XXcrTcLOPZMUyWhwfn9h7ADzH9f1wwjH6dN4q5Td0Ypea |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+dose-ranging%2C+parallel+group%2C+split-face%2C+single-blind+phase+II+study+of+light+emitting+diode-red+light+%28LED-RL%29+for+skin+scarring+prevention%3A+study+protocol+for+a+randomized+controlled+trial&rft.jtitle=Trials&rft.au=Nguyen%2C+Julie+K.&rft.au=Weedon%2C+Jeremy&rft.au=Jakus%2C+Jeannette&rft.au=Heilman%2C+Edward&rft.date=2019-07-15&rft.issn=1745-6215&rft.eissn=1745-6215&rft.volume=20&rft.issue=1&rft_id=info:doi/10.1186%2Fs13063-019-3546-6&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_s13063_019_3546_6 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1745-6215&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1745-6215&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1745-6215&client=summon |